View Older Stories View More Recent Stories

Oct 15, 2019 08:30AM Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer
Oct 10, 2019 04:05PM Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019
Oct 8, 2019 06:21AM Gilead Sciences (GILD) Submits NDA for Filgotinib for Treatment of Adults With Rheumatoid Arthritis in Japan
Oct 8, 2019 02:00AM Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan
Oct 7, 2019 08:33AM Gilead Sciences (GILD) Names Merdad Parsey, MD, PhD Chief Medical Officer
Oct 7, 2019 08:30AM Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
Oct 4, 2019 08:39AM Gilead Sciences (GILD) Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV PrEP at IDWeek
Oct 4, 2019 08:30AM Gilead Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019
Oct 3, 2019 02:49PM Gilead Sciences (GILD) Announces U.S. FDA Approves Descovy for HIV Pre-Exposure Prophylaxis
Oct 3, 2019 02:49PM U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)
Sep 9, 2019 07:30AM Gilead Sciences and the Elton John AIDS Foundation Launch RADIAN Initiative to Address HIV in Eastern Europe and Central Asia (EECA)
Sep 5, 2019 01:00AM Press Release Biocartis NV: Biocartis announces H1 2019 results
Aug 26, 2019 04:34PM Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10
Aug 23, 2019 04:01PM Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Aug 15, 2019 04:02PM UPDATE: Gilead Sciences (GILD), Galapagos NV (GLPG) Report EMA Validates Marketing Application for Filgotinib for Treatment of Rheumatoid Arthritis
Aug 15, 2019 04:01PM European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Aug 9, 2019 08:32AM Gilead Sciences (GILD) Announces China National Medical Products Administration Approves Biktarvy for Treatment of HIV-1 Infection
Aug 9, 2019 08:30AM China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Aug 8, 2019 07:42AM Agenus (AGEN) Reports FDA Acceptance of IND Filing for AGEN2373 Triggers $7.5M Milestone Payment from Gilead Sciences Inc. (GILD)
Aug 8, 2019 06:16AM Gilead Sciences (GILD) Statement on FDA Advisory Committee's Recommendation on Descovy for PrEP
Aug 7, 2019 08:44PM Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™
Aug 6, 2019 08:00AM Ontario Provides Access to Biktarvy® for the Treatment of HIV
Jul 30, 2019 04:02PM Gilead Sciences Announces Third Quarter 2019 Dividend
Jul 23, 2019 04:00PM Gilead Sciences (GILD) Reports Latest Data in Ongoing HIV Cure Research Program
Jul 23, 2019 04:00PM Gilead Announces Latest Data in Ongoing HIV Cure Research Program
Jul 23, 2019 11:02AM Gilead Sciences (GILD) Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada
Jul 23, 2019 11:00AM Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®
Jul 22, 2019 12:01PM Gilead Sciences (GILD) Presents New Data on Biktarvy for Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance
Jul 22, 2019 12:00PM Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance
Jul 22, 2019 11:01AM Gilead Sciences (GILD) Presents Proof-of-Concept Data for GS-6207 in People with HIV
Jul 22, 2019 11:00AM Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV
Jul 18, 2019 08:36AM Gilead Sciences (GILD) to Present New Data on HIV Prevention, Treatment and Cure Research at IAS
Jul 18, 2019 08:30AM Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019
Jul 17, 2019 08:33AM Gilead Sciences (GILD) Announces Chief Scientific Officer John McHutchison to Leave Company
Jul 17, 2019 08:31AM Gilead Sciences (GILD) Announces Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing
Jul 17, 2019 08:30AM Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company
Jul 17, 2019 08:30AM Gilead Sciences Announces Changes to Senior Leadership Team
Jul 16, 2019 04:05PM Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019
Jul 16, 2019 08:30AM Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
Jul 11, 2019 04:31PM Gilead Sciences (GILD) Appoints Christi L. Shaw as CEO of Kite
Jul 11, 2019 04:30PM Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite
Jul 11, 2019 08:30AM Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)
Jul 2, 2019 06:42AM Gilead Sciences (GILD) to Submit Filgotinib NDA This Year
Jul 1, 2019 07:00PM Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year
Jun 26, 2019 11:30AM Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease
Jun 3, 2019 09:00AM Kite Announces New Yescarta® Data From ZUMA-1
Jun 3, 2019 05:52AM Gilead Sciences (GILD) Subsidiary Kite Reports End of Phase 1 ZUMA-3 Results for KTE-X19 at ASCO 2019 Meetings
Jun 1, 2019 06:00PM Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
May 29, 2019 08:31AM Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
May 21, 2019 04:01PM Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5
View More Recent Stories View Older Stories